tetano
Editor, Senior Moderator
Int J Surg
. 2022 Jan 19;106233.
doi: 10.1016/j.ijsu.2022.106233. Online ahead of print.
Bovine-derived antibodies and camelid-derived nanobodies as biotherapeutic weapons against SARS-CoV-2 and its variants: A review Article
AbdulRahman A Saied[SUP] 1 [/SUP], Asmaa A Metwally[SUP] 2 [/SUP], Moses Alobo[SUP] 3 [/SUP], Jaffer Shah[SUP] 4 [/SUP], Khan Sharun[SUP] 5 [/SUP], Kuldeep Dhama[SUP] 6 [/SUP]
Affiliations
Abstract
The Coronavirus 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected 305 million individuals worldwide and killed about 5.5 million people as of January 10, 2022. SARS-CoV-2 is the third major outbreak caused by a new coronavirus in the previous two decades, following SARS-CoV and MERS-CoV. Even though vaccination against SARS-CoV-2 is considered a critical strategy for preventing virus spread in the population and limiting COVID-19 clinical manifestations, new therapeutic drugs, and management strategies are urgently needed, particularly in light of the growing number of SARS-CoV-2 variants (such as Delta and Omicron variants). However, the use of conventional antibodies has faced many challenges, such as viral escape mutants, increased instability, weak binding, large sizes, the need for large amounts of plasma, and high-cost manufacturing. Furthermore, the emergence of new SARS-CoV-2 variants in the human population and recurrent coronavirus spillovers highlight the need for broadly neutralizing antibodies that are not affected by an antigenic drift that could limit future zoonotic infection. Bovine-derived antibodies and camelid-derived nanobodies are more potent and protective than conventional human antibodies, thanks to their inbuilt characteristics, and can be produced in large quantities. In addition, it was reported that these biotherapeutics are effective against a broad spectrum of epitopes, reducing the opportunity of viral pathogens to develop mutational escape. In this review, we focus on the potential benefits behind our rationale for using bovine-derived antibodies and camelid-derived nanobodies in countering SARS-CoV-2 and its emerging variants and mutants.
Keywords: Antibodies; Bovine; COVID-19; Camelide; Nanobodies; Omicron; SARS-CoV-2; Vaccines; Variants.
. 2022 Jan 19;106233.
doi: 10.1016/j.ijsu.2022.106233. Online ahead of print.
Bovine-derived antibodies and camelid-derived nanobodies as biotherapeutic weapons against SARS-CoV-2 and its variants: A review Article
AbdulRahman A Saied[SUP] 1 [/SUP], Asmaa A Metwally[SUP] 2 [/SUP], Moses Alobo[SUP] 3 [/SUP], Jaffer Shah[SUP] 4 [/SUP], Khan Sharun[SUP] 5 [/SUP], Kuldeep Dhama[SUP] 6 [/SUP]
Affiliations
- PMID: 35065260
- DOI: 10.1016/j.ijsu.2022.106233
Abstract
The Coronavirus 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected 305 million individuals worldwide and killed about 5.5 million people as of January 10, 2022. SARS-CoV-2 is the third major outbreak caused by a new coronavirus in the previous two decades, following SARS-CoV and MERS-CoV. Even though vaccination against SARS-CoV-2 is considered a critical strategy for preventing virus spread in the population and limiting COVID-19 clinical manifestations, new therapeutic drugs, and management strategies are urgently needed, particularly in light of the growing number of SARS-CoV-2 variants (such as Delta and Omicron variants). However, the use of conventional antibodies has faced many challenges, such as viral escape mutants, increased instability, weak binding, large sizes, the need for large amounts of plasma, and high-cost manufacturing. Furthermore, the emergence of new SARS-CoV-2 variants in the human population and recurrent coronavirus spillovers highlight the need for broadly neutralizing antibodies that are not affected by an antigenic drift that could limit future zoonotic infection. Bovine-derived antibodies and camelid-derived nanobodies are more potent and protective than conventional human antibodies, thanks to their inbuilt characteristics, and can be produced in large quantities. In addition, it was reported that these biotherapeutics are effective against a broad spectrum of epitopes, reducing the opportunity of viral pathogens to develop mutational escape. In this review, we focus on the potential benefits behind our rationale for using bovine-derived antibodies and camelid-derived nanobodies in countering SARS-CoV-2 and its emerging variants and mutants.
Keywords: Antibodies; Bovine; COVID-19; Camelide; Nanobodies; Omicron; SARS-CoV-2; Vaccines; Variants.